“Bringing innovative protein technology to the research community is a key goal of New England Biolabs” said Dr. Peter Nathan, Director of Global Business Development at NEB. “This agreement will make the PURE system technology broadly available through NEB’s global distribution network, and allows for exceptional technical support for this application”. The first product released by NEB that utilizes this unique method of in vitro transcription/translation is the PURExpress™ In Vitro Protein Synthesis Kit.
"PURExpress is probably the best system available for transcribing and translating a DNA sequence to generate a small amount of pure protein to test its biochemical activity”, said Dr. Richard J. Roberts, Chief Scientific Officer at NEB and 1993 Nobel Laureate in Physiology or Medicine. “The biggest advantage of PURExpress is that it results in a product that is not contaminated with nucleases, proteases or other unwanted activities that often contaminate in vitro transcription/translation systems made from cell extracts. Further, because PURExpress is made from purified components, rigorous quality testing can be conducted and its purity assured. My laboratory has used it successfully to test the biochemical activity of gene products predicted computationally”.
Ning Sun, the corporate advisor to PGI in the USA, comments “ NEB is a well established company that develops, manufactures and distributes a large number of recombinant enzymes world-wide. As such, we are very pleased that NEB recognizes the excellence of this protein expression system, and we look forward to NEB developing the PURE system into a successful product line”.
About PGI
Post Genome Institute Co., Ltd. (PGI) is a Japanese bio-venture company that acquires unused revolutionary biotechnologies from both academia and industrial fields. PGI develops outstanding post-genomic technologies and brings them to the market. PGI also establishes infrastructure technologies for drug discovery and tailor-made medicine. For more information about Post Genome Institute, visit www.postgenome.jp.
About NEB
Established in the mid 1970’s, New England Biolabs, Inc. leads the industry in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genome research. NEB continues to expand its product offerings into areas related to PCR, cloning, expression and purification, and is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.
